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Electron paramagnetic resonancethat the lipid matrix of neuronal cell membranes plays an important role in the
accumulation of β-amyloid peptides into senile plaques, one of the hallmarks of Alzheimer's disease (AD).
With the aim to clarify the molecular basis of the interaction between amyloid peptides and cellular
membranes, we investigated the interaction between a cytotoxic fragment of Aβ(1–42), i.e., Aβ(25–35), and
phospholipid bilayer membranes. These systems were studied by Electron Paramagnetic Resonance (EPR)
spectroscopy, using phospholipids spin-labeled on the acyl chain. The effect of inclusion of charged
phospholipids or/and cholesterol in the bilayer composition was considered in relation to the peptide/
membrane interaction. The results show that Aβ(25–35) inserts in bilayers formed by the zwitterionic
phospholipid dilauroyl phosphatidylcholine (DLPC), positioning between the outer part of the hydrophobic
core and the external hydrophilic layer. This process is not signiﬁcantly inﬂuenced by the inclusion of the
anionic phospholipid phosphatidylglycerol (DLPG) in the bilayer, indicating the peptide insertion to be driven
by hydrophobic rather than electrostatic interactions. Cholesterol plays a fundamental role in regulating the
peptide/membrane association, inducing a membrane transition from a ﬂuid-disordered to a ﬂuid-ordered
phase. At low cholesterol content, in the ﬂuid-disordered phase, the insertion of the peptide in the
membrane causes a displacement of cholesterol towards the more external part of the membrane. The
crowding of cholesterol enhances its rigidifying effect on this region of the bilayer. Finally, the cholesterol-
rich ﬂuid-ordered membrane looses the ability to include Aβ(25–35).
© 2008 Elsevier B.V. All rights reserved.1. Introduction
In the century which has passed since 1907, when Alois Alzheimer
published the ﬁrst report on the neurodegenerative disorder that now
bears his name [1], the incidence of Alzheimer disease (AD) has
enormously increased [2]. Themain reason for this probably lies in the
increase in average human life expectancy. Nowadays AD is the most
common form of senile dementia, affecting up to 15 million
individuals worldwide. Because of the ongoing increase in life
expectancy, by 2050 we can expect approximately 25% of people
living in the Western hemisphere to be over 65 years of age, one third
of whom are likely to develop AD.
AD is characterised by progressive memory deﬁcit, cognitive
impairment and personality changes. From a morphological view-
point, the main features of AD are [3]: i. accumulation of extracellular
amyloid plaques, triggered by the aggregation of the β-amyloidaolo Corradini”, Università di
intia, 80126, Napoli, Italy. Tel.:
ico).
ll rights reserved.peptides (Aβ), in the brain of affected individuals; ii. presence of
intracellular neuroﬁbrillary tangles, which consist mainly of aggre-
gated forms of protein tau.
The Aβ peptides present a length ranging between 39 and 43
amino acids; they are derived by cleavage of the amyloid precursor
protein (APP) in the transmembrane region by a γ-secretase and at its
N-terminus by a β-secretase [4]. The patho-physiological role of these
peptides in causing AD is not yet assessed. In the past years amyloid
plaqueswere generally regarded as the cause of the cognitive disorder.
More recently, the relevance of soluble protoﬁbrillar oligomeric forms
of Aβ has been recognised [5]. Particularly, it has been shown in vivo
that the neurotoxic effect of Aβ(1-42) is independent of plaques
formation [6] and that protoﬁbrillar intermediates of Aβ induce
progressive neurotoxicity in cortical neurons [7].
In the Aβ peptides sequence, the residues from 29 to the C-
terminus belong to the transmembrane domain of APP, and conse-
quently these peptides are expected to favourably interact with lipid
membranes, both as monomers and in aggregated forms [8,9]. Various
studies have been conducted in the attempt to explore the molecular
basis of interactions between Aβ peptides and cellular membranes
[10,11]. Particularly, researchers have focused their attention on the
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35), and phospolipid bilayers of different composition and net
charge. However, the conclusions are still controversial and, to some
extent, contradictory. Terzi et al., by analysing circular dichroism and
calorimetry data, proposed the adsorption of the peptide on the
surface of anionic bilayer, driven by electrostatic interactions, to be
the predominant phenomenon; according to the same authors no
interaction would occur between Aβ(25–35) and uncharged mem-
branes [11]. A similar conclusion was drawn by Martínez-Senac et
al., on the basis of infrared spectroscopy evidences [12]. In contrast,
the analysis of X-ray diffraction pattern led Mason et al. to the
conclusion that Aβ(25–35) inserts into the hydrocarbon core of
uncharged lipid bilayers [13]. Successively, Dante et al. performed a
very accurate and detailed analysis of the interaction between
Aβ(25–35) and lipid bilayers by using the neutron diffraction
technique. These authors evidenced the partitioning of the peptide
in two populations, one inserted quite deeply in the bilayer core and
the other one adsorbed on the bilayer surface. The relative ratio of
these two populations is determined by the phospholipids net
charge, in the direction that an excess negative charge increases the
fraction of external peptides [14,15]. More recently, Lau et al. pointed
out that, in in vitro experiments employing model membranes, the
Aβ(25–35) location could depend on the procedure through which
the samples are prepared: when added after liposome formation,
the peptide preferentially interacts with the lipid head-groups; when
included during liposome formation, it inserts deeper into the bilayer
[16].
Another aspect that has attracted the researchers' interest is the
effect of cholesterol on the Aβ insertion into a lipid bilayer. Cholesterol
is an essential component of animal cellular membranes and is well
known for inﬂuencing the membrane ﬂuidity, permeability and
dielectric properties. A large body of data has been collected in an
attempt to clarify how enrichment or depletion of membrane
cholesterol relates to AD. The results, reviewed in Puglielli et al. [17],
Wolozin [18] and Ledesma et al. [19], are highly controversial. From
one side, the cholesterol content in neuronal cells of AD patients has
been found to be low [20]. In contrast, an inhibiting effect of
cholesterol on channel formation of Aβ in lipid bilayers, thus
preserving the membrane functionality, has been reported [21].
Concerning the fragment Aβ(25–35), a recent work by Dante et al.
has put in evidence, by neutron diffraction, that high levels of
cholesterol inhibit the insertion of Aβ(25–35) in lipid bilayers [22].
Electron Paramagnetic Resonance (EPR) spectroscopy, by using
spin-labeled substances, has proved to be a fruitful experimental
approach to the study of the interactions between peripheral as well
as integral proteins and membranes. Both the protein, or the
polypeptide, and the lipid can be labeled, so that the systems can be
studied by different “points of view”. In a previous work we
investigated the interaction of spin-labeled Aβ(25–35) with surfactant
micelles and phospholipid liposomes, ﬁnding that the C-terminal
portion of the peptide is highly associated to the aggregates, while the
N-terminal part extends into the external aqueous medium with
occasional contacts with the lipid head-group region [23]. Particularly,
the interaction of the C-terminal portion of the peptide is enhanced
with charged bilayers.
An alternative approach is the study of peptide–membrane
interaction by using spin-labeled lipids. By this way, surface associa-
tion can be distinguished from membrane penetration and trans-
membrane insertion by the characteristic effects on the lipid chain
mobility that are registered in the spin-label spectrum [24,25]. EPR is
well suited to this kind of investigation, because its dynamic
sensitivity is optimally matched to the timescale of the rotational
motions of the lipids in biological membranes. In this work, we
investigate the Aβ(25–35)–membrane interaction by using phospho-
lipid EPR probes that are labeled on the acyl chain. The effect of both
the bilayer charge and the presence of cholesterol have beeninvestigated, in the attempt to clarify the molecular bases of the
peptide–membrane interaction.
2. Materials and methods
2.1. Materials
Dilauroyl phosphatidylcholine and phosphatidylglycerol (DLPC
and DLPG) were obtained from Avanti Polar Lipids (Alabaster, AL,
USA). Spin-labeled phosphatidylcholine (1-acyl-2-[n-(4,4-dimethy-
loxazolidine-N-oxyl)]stearoyl-sn-glycero-3-phosphocholine, n-PCSL)
with the nitroxide group at two different positions, n=5 or n=12, in
the sn-2 acyl chain, were also purchased from Avanti Polar Lipids. The
spin-labels were stored at −20 °C in ethanol solutions at a
concentration of 1 mg/mL. Cholesterol (CHOL) was obtained from
Sigma (St. Louis, MO, USA).
2.2. Peptide synthesis
The Aβ(25–35) amyloid peptide, GSNKGAIIGLM, was manually
synthesized by conventional solid-phase chemistry using the Fmoc/
tBu strategy. The TentaGel S RAM (0.20 mmol/g capacity) resin was
purchased from Fluka (St. Louis, MO, USA). After deprotection of the 9-
ﬂuorenylmethoxycarbonyl (Fmoc) group with 30% piperidine in N,N-
Dimethylformamide (DMF), the amino acids in 4 fold excess were
coupled with the growing peptide chain, using DMF solution with an
equimolar excess of 1-Hydroxybenzotriazole (HOBt) and 2-(1H-
benzotriazol-1-yl-1,1,3,3-tetramethyluronium hexaﬂuorophosphate
(HBTU). Peptide–resin cleavage and side chain deprotection reactions
were carried out in 95% Triﬂuoroacetic acid (TFA), 2.5% water and 2.5%
Triisopropylsilane (TIS). The resin was ﬁltered, and the solution added
drop wise to cold tert-butylmethyl ether in order to precipitate the
peptide. All the reagents were from Novabiochem (Darmstadt,
Germany) or Sigma Aldrich; solvents used in peptide synthesis were
obtained from Carlo Erba (Milano, Italy) and used without further
puriﬁcation.
Analytical HPLC was carried out with a System Gold 125 s model
(Beckmann Coulter, Fullerton, CA, USA) equipped with a UV166
detector. Preparative HPLC was carried out with aWaters 600E system
controller equipped with a 486 UV detector (Waters, Milford, MA,
USA). A Jupiter (Phenomenex, Torrance, CA, USA) C18 column
(25×4.6 cm, 5 μm, 300 Å pore size) was used for analytical runs and
a Vydac (Hesperia, CA, USA) C18 column (25×10 cm, 5 μm, 300 Å pore
size) was used for peptide puriﬁcation. Analytical separations were
performed with a linear gradient (5–50% in 45 min) of CH3CN inwater
containing 0.1% TFA. Flow rate: 1 ml/min. UV detection: 210 nm. The
sample purity wasN98%. The peptide was characterized by mass
spectra analysis with a Finnigan LCQ-Deca ion trap instrument
equipped with an electrospray source (LCQ-Deca Finnigan, Milano,
Italy); samples were directly infused in the ESI source by using a
syringe pump at a ﬂow rate of 5 μL/min. Data were analyzed with
Xcalibur software.
Unstructured peptide aggregates, which are often present in dry
samples from synthesis, can severely hamper solubility [26]. For this
reason, peptide samples to be used in EPR experiments were treated
with triﬂuoroacetic acid immediately before being dissolved in the
ﬁnal mixture.
2.3. Sample preparation
Samples of DLPC multi lamellar vesicles (MLV) for EPR spectro-
scopy were prepared as follows: 20 μg of DLPC, dissolved in a CH2Cl2–
methanol mixture (2:1 v/v), and 1% (wt/wt) of the spin-label,
dissolved in ethanol, were thoroughly mixed, and a thin lipid ﬁlm
was produced by evaporating the solvents with dry nitrogen gas. Final
traces of solvents were removed by subjecting the sample to vacuum
Fig. 1. EPR spectra of 5-PCSL in DLPC/CHOL bilayer membranes, in the absence (solid
line) and in the presence (dashed line) of 1:1 wt/wt Aβ(25–35).
Fig. 2. EPR spectra of 12-PCSL in DLPC/CHOL bilayer membranes, in the absence (solid
line) and in the presence (dashed line) of 1:1 wt/wt Aβ(25–35).
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of 10 mM phosphate buffer, gently warmed at ∼35 °C, and repeatedly
vortexed. The lipid suspension thus obtained was transferred into a
25 μL glass capillary.
MLV's of DLPC including also DLPG and/or CHOL were prepared by
the same procedure, mixing appropriate amounts of lipid or sterol
solutions in CH2Cl2–methanol before evaporation of the organic
solvents.
Samples containing the peptide–lipid complex were prepared in a
similar manner, except that the lipid ﬁlm was hydrated directly with
the peptide solution in phosphate buffer.
2.4. EPR measurements
EPR spectra were recorded with a 9 GHz Bruker Elexys E-500
spectrometer (Bruker, Rheinstetten, Germany). Samples were placed
in 25 μL glass capillaries and ﬂame sealed. The capillaries were placed
in a standard 4 mm quartz sample tube containing light silicone oil
for thermal stability. All the measurements were performed at 25 °C.
Spectra were recorded using the following instrumental settings:
sweep width, 120 G; resolution, 1024 points; time constant, 20.48 ms;
modulation frequency, 100 kHz; modulation amplitude, 1.0 G;
incident power, 6.37 mW. Several scans, typically 16, were accumu-
lated to improve the signal-to-noise ratio. Values of the outer
hyperﬁne splitting, 2Amax, were determined by measuring the
difference between the low-ﬁeld maximum and the high-ﬁeld
minimum, through a home-made, MATLAB-based software routine.
The main source of error on the 2Amax value is the uncertainty in
composition of samples prepared by mixing few microliters of
mother solutions. For this reason, reproducibility of 2Amax determi-
nation was estimated by evaluating its value for selected indepen-
dently prepared samples with the same nominal composition. It was
found to be±0.2–0.3 G. In general, 2Amax is dependent on both the
amplitude (i.e., order) and rate of chain rotational motion [27], and istherefore a useful parameter for characterising chain dynamics in
phospholipid membranes.
3. Results
3.1. Effect of inclusion of charged lipids and cholesterol in phospholipid
membranes
As a preliminary part of our research, we investigated DLPC
membranes incorporating phosphatidylcholine spin-labeled on the 5
C-atom of the sn-2 chain (5-PCSL). This label presents the nitroxide
group close to its hydrophilic headgroup. The EPR spectrum of 5-PCSL
in DLPC membranes, shown in Fig. 1 (lower spectrum, solid line),
presents a clearly deﬁned axially anisotropic lineshape, with a value of
the outer hyperﬁne splitting, 2Amax, equal to 49.6±0.1 G. We also
investigated DLPC membranes including phosphatidylcholine spin-
labeled on the 12 C-atom of the sn-2 chain (12-PCSL), in which the
nitroxide group is positioned close to the terminal methyl region of
the chain. In this case a narrow three-line, quasi-isotropic spectrum is
obtained, see Fig. 2 (lower spectrum, solid line). The higher isotropy of
the 12-PCSL spectrum with respect to that obtained for 5-PCSL
indicates a ﬂexibility increase in segmental chain mobility in going
from the polar headgroups to the inner hydrophobic core, which is a
characteristic hallmark of the liquid-crystalline state of ﬂuid phos-
pholipid bilayers [28].
The effect of the inclusion of charged phospholipid on the bilayer
ﬂuidity, as monitored by 5-PCSL, has been investigated by substituting
a fraction of the zwitterionic phospholipid DLPC with its anionic
analogue, DLPG. Inspection of Fig. 3, open circles, shows that the 2Amax
values very slightly increase with the DLPG content (note, however,
the expanded ordinate axis of the ﬁgure). This indicates that the
electrostatic repulsion among the charged DLPG headgroups on the
bilayer surface induces a weak structuring effect.
Fig. 5. Outer hyperﬁne splitting, 2Amax, of 12-PCSL in DLPC/CHOL bilayers as a function
of the cholesterol content, in the absence (open circles) and in the presence of 1:1 wt/wt
Aβ(25–35) with respect to total lipids (solid circles).
Fig. 3.Outer hyperﬁne splitting, 2Amax, of 5-PCSL in DLPC/DLPG bilayers as a function of
the DLPG content, in the absence (open circles) and in the presence of 1:1 wt/wt
Aβ(25–35) (solid circles).
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membranes, at various concentrations of cholesterol. Selected EPR
spectra of 5-PCSL in DLPC/CHOL lipid samples are shown in Fig. 1, solid
lines; for all investigated samples, a clearly deﬁned axially anisotropic
spectrum is obtained. Inspection of the ﬁgure shows signiﬁcant
perturbations due to the presence of cholesterol. The dependence of
the outer hyperﬁne splitting, 2Amax, on the CHOL content in the
bilayer is reported in Fig. 4, open circles. A sharp increase in 2Amax is
evident at ca. 20%wt/wt cholesterol on total lipids, putting in evidence
a decrease in lipid chain mobility; addition of cholesterol above 30%
wt/wt results in a more limited 2Amax increase. This evidence should
be related to the well-established transition of the lipid bilayer
structure from a CHOL-poor ﬂuid lamellar phase, Lα, to a CHOL-rich
ﬂuid-ordered phase, L01 [29,30].
Interestingly, the corresponding change in the 12-PCSL spectrum is
more gradual than that observed in the 5-PCSL one, see Fig. 2. In an
attempt to easily quantify this evidence, also in the case of 12-PCSL
spectra in DLPC/CHOL membranes we determined the outer hyperﬁne
splitting, 2Amax. The results are shown in Fig. 5, open circles, and
conﬁrm that no sharp transition can be detected with this label.
Addition of CHOL to the partially charged DLPC/DLPG membranes
leads to an increase in the 2Amax value of included 5-PCSL. However,
the trend, reported in Fig. 6, shows a linear 2Amax increase, different
from the sigmoid registered in DLPC bilayers (see Fig. 4). Thus, the
quite abrupt transition from disordered to ordered ﬂuid phases is
substituted by a gradual bilayer structuring.Fig. 4. Outer hyperﬁne splitting, 2Amax, of 5-PCSL in DLPC/CHOL bilayers as a function of
the cholesterol content, in the absence (open circles) and in the presence of 1:1 wt/wt
Aβ(25–35) with respect to total lipids (solid circles).3.2. Effect of the bilayer charge on the interaction of Aβ(25–35) with
phosphatidylcholine and phosphatidylcholine/phosphatidylglycerol
membranes
The association of Aβ(25–35) with lipid membranes can be
detected by the perturbation of the chain mobility of spin-labeled
lipids, by using EPR spectroscopy as found for classical water-soluble
peripheral membrane proteins and derived peptides [31,32]. Addition
of Aβ(25–35) to pure DLPC bilayers, at a 1:1 wt/wt ratio, signiﬁcantly
affects the 5-PCSL spectrum, see Fig. 1, dashed line. In fact, the
peptide causes a slight but signiﬁcant 2Amax increase (from 49.6±
0.1 G to 50.4±0.2 G), i.e., the mobility of the spin-labeled chains
decreases by interaction of the peptide with the membrane. Restric-
tion in the mobility of phospholipid acyl chains interacting with the
peptide was detected also by other experimental techniques, such as
solid-state NMR [16]. In contrast, the addition of Aβ(25–35) to pure
DLPC bilayers does not causes any change in the 12-PCSL spectrum,
see Fig. 2.
The electrostatic contribution in driving the association of Aβ(25–
35) with lipid membranes has been monitored by substituting a
fraction of the zwitterionic phospholipid DLPC with its anionic
analogue, DLPG. At all the considered DLPG concentrations, addition
of 1:1 wt/wt Aβ(25–35) with respect to total lipids leads to a 2Amax
increase, see Fig. 3. This variation is almost unaffected by the DLPG
concentration, i.e. by the bilayer surface charge.Fig. 6. Outer hyperﬁne splitting, 2Amax, of 5-PCSL in DLPC/DLPG/CHOL bilayers as a
function of the cholesterol content, in the absence (open squares) and in the presence of
1:1 wt/wt Aβ(25–35) (solid squares). In all samples the DLPC/DLPG ratio is 70:30 wt/wt.
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phosphatidylcholine and phosphatidylcholine/phosphatidylglycerol
membranes
Addition of 1:1 wt/wt Aβ(25–35) with respect to total lipids
signiﬁcantly affects the 5-PCSL spectra in DLPC/CHOL membranes
(Fig. 1) and the consequent 2Amax trend with cholesterol content
(Fig. 4, solid circles). With introducing cholesterol in the mem-
brane, the variation of the 2Amax value due to the presence of the
peptide increases, reaching a maximum at a cholesterol content equal
to 20% wt/wt, see Figs. 1 and 4. However, at higher cholesterol
content the 5-PCSL spectrum is not affected by the presence of the
peptide.
The effect of the addition of Aβ(25–35) on the 12-PCSL spectra in
DLPC/CHOL membranes is shown in Fig. 2. At a 20% wt/wt CHOL
content, a quasi-isotropic spectrum is obtained in the presence of the
peptide, as opposed to the clearly deﬁned axially anisotropic spectrum
obtained in its absence. This is particularly revealed by the loss of the
second high-ﬁeld minimum. At higher cholesterol content the
spectrum lineshape is not affected by the presence of the peptide
anymore. The 2Amax trend conﬁrms what is inferred from the spectra.
In fact, at a CHOL contentb30% wt/wt the presence of the peptide
causes a signiﬁcant 2Amax lowering with respect to that registered in
its absence, while at higher CHOL content the 2Amax value is not
perturbed by the peptide.
In the presence of Aβ(25–35), the introduction of CHOL in DLPC/
DLPG (70:30wt/wt)membranes causes an initial increase in the 2Amax
value due to the presence of the peptide. This variation reaches a
maximum at a CHOL content equal to 10% wt/wt, see Fig. 6. At higher
cholesterol content the 5-PCSL spectrum is affected no more by the
presence of the peptide.
3.4. Peptide-lipid titration
Fig. 7 shows the outer hyperﬁne splitting, 2Amax, of 5-PCSL in
DLPC/CHOL membranes, at 0, 10, and 20% wt/wt cholesterol on total
lipids, with increasing Aβ(25–35) concentration. In all curves, a typical
binding saturation trend is registered: the decrease in lipid chain
mobility saturates at a weight ratio of added peptide to total lipids of
approximately 20% wt/wt peptide on total lipids. In the case of pure
DLPC liposomes, this corresponds to ca. 8 lipids per peptide. The
evidence that the saturation value does not decrease with increasing
the fraction of cholesterol in the bilayer, suggests that some
cholesterol molecules come in direct contact with the peptide,
substituting the DLPC ones.Fig. 7. Dependence of the outer hyperﬁne splitting increase, 2Amax, of 5-PCSL on
Aβ(25–35)/total lipid ratio for DLPC/CHOL bilayers at 0 (solid circles), 10 (solid squares)
and 20% cholesterol (solid diamonds).4. Discussion
Alzheimer's disease is a member of the heterogeneous family of
diseases referred to as amyloidosis, characterized by deposits mainly
formed by amyloid peptides in a variety of organs [33]. There is nowan
increasing amount of evidence that amyloid toxicity involves interac-
tion with plasma membranes. As an example, this has been shown in
the case of the human Islet Amyloid PolyPeptide (IAPP), a type-2-
diabetes-related peptide that interacts in monomeric form with the
plasma membrane of pancreatic β-cells [34–36].
In the same way, it is now widely accepted that Aβ peptide
neurotoxicity is mediated by direct interaction between the peptide
and the cellular membrane, through a still controversial mechanism.
However, the effect of this interaction, i.e. whether it favours or not AD
evolution, is unclear. In fact, from one side, retention of monomeric
peptide in the membrane should hinder its accumulation in the
external medium and, consequently, ﬁbrils and plaques formation. On
the other side, intercalation of Aβ oligomers in the membrane could
result in ion-permeable channels formation, and thus in cell death [9].
With the aim to explore the molecular basis of the interaction
between amyloid peptides and cellular membranes, we investigated
the interactions between Aβ(25–35) and phospholipid bilayers.
Obvious cautions have to be paid when generalising conclusions
drawn from study involving a peptide fragment to biological systems
in which the full-length peptide is present. Nevertheless, some
indications can be obtained. Indeed, Aβ(25–35) is generally consid-
ered as the biologically active region of Aβ because it represents the
shortest fragment that exhibits large β-sheet aggregated structures
and because it retains the toxicity of the full-length peptide [37];
furthermore, it is also able to induce ion-channel formation in
phospholipid membranes [38].
Particularly, in our work the effect of the peptide presence on the
bilayer structure and dynamics has been monitored by spin-label EPR
spectroscopy. Liposomes of the zwitterionic phospholipid DLPC have
been initially considered as biomembrane-mimicking systems. At the
temperature at which our investigation has been performed (25 °C),
DLPC acyl chains are in the ﬂuid-phase state, which may amplify
interaction with guest molecules [32]. By using two spin-labels
presenting the nitroxide group in different position along the
hydrophobic alkyl chain, it was possible to investigate the depth of
peptide penetration into the bilayer. The results show that the
mobility of the spin-label 5-PCSL is signiﬁcantly affected by the
presence of the peptide, while that of 12-PCSL is almost unperturbed.
Results similar to those obtained for 12-PCSL were seen with 14-PCSL
(data not shown). This evidence indicates that Aβ(25–35) inserts in
DLPC positioning between the outer part of the hydrophobic core and
the external hydrophilic layer. These results are in only partial
agreement with those reported by Dante et al. [14], who proposed a
deeper penetration of Aβ(25–35) in the bilayer core. However, our
ﬁndings are in agreement with those of a previous EPR study by some
of us [23], in which, using two spin-labeled Aβ(25–35) analogues
containing the nitroxide group of the amino acid TOAC as a
paramagnetic probe at the N- or the C-terminus of the peptide
sequence, respectively, it was found that the C-terminal portion of the
peptide is embedded in the interior of the membrane, while the N-
terminal part extends into the aqueous phasewith occasional contacts
with the lipid head-group region.
Indeed, the Aβ(25–35) three-dimensional structure in a mem-
brane-mimicking environment has been solved by NMR study [39,40]
revealing the propensity of the seven amino acids residues in the
hydrophobic C-terminal region of the peptide to assume a turn-helical
structure, most likely embedded in the membrane, whereas the four
residues of the N-terminus, including a positively charged lysine,
would be in the vicinity of the hydrophilic environment. From the
NMR-derived structure, it can be valuated that the length of the
hydrophobic region inserting in the apolar core of the bilayer is about
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saturated alkyl chains, it is possible to estimate that this length
corresponds to about 8 methylenes; i.e. it is expected that the peptide
insertion can directly perturb the motion of the alkyl chain down to
the position 8, which is in agreement with our result.
In order to discriminate the driving force of the Aβ(25–35)/
membrane interaction, we investigated how increasing amounts of
the anionic phospholipid DLPG inﬂuence the peptide insertion. It was
found that the membrane net charge only slightly affects the 5-PCSL
spectrum variation due to the presence of the peptide, see Fig. 3. This
evidence indicates that the hydrophobic interactions play a major role
in driving the peptide/membrane interaction. It is to be noted that our
experimental approach is tailored to detect the penetration of a guest
molecule in the bilayer. Consequently, we cannot exclude that a
fraction of Aβ(25–35) molecules adsorbs onto the bilayer surface, as
recently reported by Dante et al. [14,15], and that this process is
somehow inﬂuenced by the bilayer net charge. However, the
similarity of the 5-PCSL spectra in DLPC and DLPC/DLPG membranes
in the presence of the peptide leads us to suggest that the eventual
electrostatic interaction between the bilayer external surface and the
peptide is not markedly effective in causing a massive “extrusion” of
the peptide from its location in the bilayer structure.
In this connection, Lau et al. have recently pointed out that the
Aβ(25–35) positioning with respect to lipid bilayers could depend on
the sample preparation procedure, i.e., it interacts with the head-
groups if added after liposome preparation, while it inserts in the
bilayer if inserted during liposome preparation [16]. We tested
samples prepared through different procedures, ﬁnding negligible
differences in the EPR spectra (data not shown). Indeed, it is possible
that the procedure could affect an eventual partitioning of the peptide
in two populations, one adsorbed on the bilayer surface and the other
one inserted quite deeply in the bilayer core [14,15], and that our
experimental approach, for the reasons discussed above, is not sen-
sitive to this change.
The presence of cholesterol modulates the Aβ(25–35)/bilayer
interaction. Cholesterol is a major component of mammalian cells
and is known to inﬂuence membrane thickness and ﬂuidity. In the
case of DLPC bilayers at room temperature, the presence of
cholesterol amounts≥20% wt/wt induces a transition from a ﬂuid-
disordered to a ﬂuid-ordered phase, as clearly detected by 5-PCSL
EPR spectra. In turn, the ﬂuidity of the membrane, as modulated by
the cholesterol content, regulates the insertion of the Aβ(25–35)
peptide. In the ﬂuid-disordered phase the presence of cholesterol
enhances the changes in the 5-PCSL spectrum due to the presence of
the peptide. This indicates that the peptide is still able to penetrate
the bilayer and that cholesterol and peptide exert a synergistic
rigidifying action on the bilayer structure. At the same time, in the co-
presence of cholesterol and peptide the 12-PCSL spectrum shows that
the inner part of the hydrophobic tail is more ﬂexible than in the
presence of cholesterol alone. This evidence indicates that the
insertion of the peptide causes a re-positioning of cholesterol closer
to the hydrophilic external layer. A similar effect has been recently
reported in the literature for the full-length Aβ peptide [41].
However, as the cholesterol content exceeds 30% wt/wt, i.e. in the
ﬂuid-ordered bilayer, the peptide insertion appears to be inhibited
completely. This is consistent with the literature data indicating that
cholesterol preserves the bilayer integrity from the disrupting effect
of the amyloid peptide [42].
In the presence of DLPG, i.e. for charged membranes, the transition
of lipid membrane from the ﬂuid-disordered to the ﬂuid-ordered
phase, induced by increasing the cholesterol content in the bilayer, is
much broader, as indicated by the gradual change in the 5-PCSL
spectrum. Also in this case, low amounts of cholesterol seem to favour
the peptide penetration while a further increase of the cholesterol
content results in peptide-depletedmembranes. Comparison between
uncharged and charged bilayer systems, indicates that exclusion of thepeptide from the membrane occurs at lower cholesterol content (20%
rather than 30% wt/wt) in the latter case, suggesting a certain degree
of synergism of cholesterol and DLPG in disfavouring Aβ(25–35)
insertion in the membrane. Intriguingly, even though the bilayer used
in this work is a simpliﬁed model system of cellular membranes, the
cholesterol content necessary for peptide release is not much higher
than that present in normal neurons (15–20% w/w [43]).
It is interesting to put the results of the present work in the
framework of the scientiﬁc debate on the subject. The role played by
cellularmembranes in the Aβ peptides formation and self-aggregation
is still highly controversial, even if an increasing number of papers
strongly supports its relevance [44]. Indeed, it is likely that
membranes play different roles in different steps of the neurodegen-
erative process. Aβ peptides sequence includes a segment of the
transmembrane domain of the precursor APP; moreover, the cleavage
of the precursor in the transmembrane region is performed by the
transmembrane enzyme γ-secretase. Thus, the membrane plays a
fundamental role in the Aβ peptides formation. Since the peptide self-
aggregation ﬁnally resulting in plaques formation occurs in the
extracellular medium, the factors favouring the peptide release from
themembrane are relevant. Furthermore, the peptide self-aggregation
occurs close to the membrane surface, so that it is well possible that
interaction between the peptides and the membrane surface could
catalyse the aggregation process [45]. Furthermore, peptides' oligo-
mers could intercalate in the membrane, causing, as reported in the
literature, a loss of the membrane functionality and the consequent
cell death [9].
Our work focused on the interaction between Aβ(25–35) in
monomeric form and phospholipid bilayers. Consequently, our results
shed light on the factors inﬂuencing the process by which the peptide,
initially positioned in the more external region of the lipid bilayer
hydrophobic core is released to the external aqueous medium. This
process is not signiﬁcantly inﬂuenced by the membrane charge, being
the peptide/membrane association driven fundamentally by hydro-
phobic interactions. In contrast, cholesterol plays a crucial role in
regulating the peptide release. Actually, this is a feature shared with
other peptides, e.g. the antimicrobials ones [46,47], even if details of
the mechanism through which cholesterol works are not completely
understood. In the case under consideration in this work, this mainly
occurs through an indirect mechanism by which cholesterol induces a
transition from a ﬂuid-ordered to a ﬂuid-disordered phase. In turn,
ﬂuid-ordered membranes loose the ability to include Aβ(25–35).
Interestingly, our results suggest also some direct cholesterol–peptide
interactions to the involved in the process. In fact, at low cholesterol
content, the insertion of the peptide in the membranes causes a
displacement of cholesterol towards the more external part of the
membrane. The crowding of cholesterol enhances its rigidifying effect
on this region of the bilayer, ﬁnally resulting in the peptide exclusion.
Because of the fundamental role played by cholesterol in ruling the
membrane plasticity, permeability and functionality, its speciﬁc
membrane location can bemore important than the absolute amount;
thus, it can be suggested that the crowding of cholesterol molecules in
the more external part of the hydrophobic core of the phospholipid
bilayer due to the insertion of the amyloid peptide can signiﬁcantly
affect the neuronal cell function.
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